Coexistence of SMA Type I with Citrate Transporter Deficiency Disorder: A Case Report

Abstract

The coexistence of spinal muscular atrophy (SMA) with other diseases has been rarely described. We report a unique case with dual pathogenic gene mutations: survival motor neuron 1 (SMN1) gene causing SMA and SLC13A5 gene causing citrate transporter deficiency-induced epilepsy (early infantile epileptic encephalopathy 25, OMIM 615905).

A girl presented with recurrent focal seizures with semiology of eyelid blinking, deviation of eyes, and facial twitches, which started on the second day of her life. Interictal EEG showed bilateral multifocal and generalized discharges. Brain MRI revealed delayed myelination and generalized volume loss. PET scan showed diffuse cortical hypometabolism. She had refractory seizures, including two episodes of status epilepticus while being treated with various antiseizure medications. Genetic analysis revealed a homozygous deletion of the SLC13A5 gene at 17p13.1. At 1 year of age, progressive hypotonia, initially ascribed to seizures and antiseizure medications, the appearance of tongue fasciculations and the need for respiratory support, prompted testing for SMA. Mutation at the SMN1 gene locus (5q11.2-13.2) was found and an SMA type I diagnosis was established. EMG/nerve conduction velocity revealed a motor neuron disorder. She was started on nusinersen at the age of 2.5 years once it became available. She was tracheostomized for bilevel positive airway pressure support. At the age of 4.5 years, she had a cardiac arrest and passed away.

This is a case report of coexistent mutations in the SMN1 and SCL13A5 genes with overlapping and diagnostically confusing features of progressive hypotonia. The constellation of these separate genetic entities constitutes a clinical phenotype that has not been reported previously.

Keywords

citrate transporter deficiency - spinal muscular atrophy

• References

• 1 Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics 2015; 12 (02) 290-302
• 2 Teoh HL, Carey K, Sampaio H, Mowat D, Roscioli T, Farrar M. Inherited paediatric motor neuron disorders: beyond spinal muscular atrophy. Neural Plast 2017; 2017: 6509493
• 3 Shababi M, Lorson CL, Rudnik-Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?. J Anat 2014; 224 (01) 15-28
• 4 Voutoufianakis S, Psoni S, Vorgia P. et al. Coinheritance of mutated SMN1 and MECP2 genes in a child with phenotypic features of spinal muscular atrophy (SMA) type II and Rett syndrome. Eur J Paediatr Neurol 2007; 11 (04) 235-239
• 5 Coutinho Dos Santos LH, Scola RH, Rosário NA, Munhoz da Rocha LE, Bruck I. Neurofibromatosis 1 associated with spinal muscular atrophy. Pediatr Neurol 2009; 40 (02) 117-119
• 6 Thevenon J, Milh M, Feillet F. et al. Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of life. Am J Hum Genet 2014; 95 (01) 113-120
• 7 Lisi EC, Cohn RD. Genetic evaluation of the pediatric patient with hypotonia: perspective from a hypotonia specialty clinic and review of the literature. Dev Med Child Neurol 2011; 53 (07) 586-599
• 8 Hardies K, de Kovel CG, Weckhuysen S. et al; autosomal recessive working group of the EuroEPINOMICS RES Consortium. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia. Brain 2015; 138 (Pt 11): 3238-3250
• 9 Klotz J, Porter BE, Colas C, Schlessinger A, Pajor AM. Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay. Mol Med 2016; 22: 310-321
• 10 Bhutia YD, Kopel JJ, Lawrence JJ, Neugebauer V, Ganapathy V. Plasma membrane Na⁺-coupled citrate transporter (SLC13A5) and neonatal epileptic encephalopathy. Molecules 2017; 22 (03) 378
• 11 Yang QZ, Spelbrink EM, Nye KL, Hsu ER, Porter BE. Epilepsy and EEG phenotype of SLC13A5 citrate transporter disorder. Child Neurol Open 2020; 7: X20931361
• 12 Matricardi S, De Liso P, Freri E. et al. Neonatal developmental and epileptic encephalopathy due to autosomal recessive variants in SLC13A5 gene. Epilepsia 2020; 61 (11) 2474-2485
• 13 Spelbrink EM, Brown TL, Brimble E, Blanco KA, Nye KL, Porter BE. Characterizing a rare neurogenetic disease, SLC13A5 citrate transporter disorder, utilizing clinical data in a cloud-based medical record collection system. Front Genet 2023; 14: 1109547
• 14 Nashabat M, Al Qahtani XS, Almakdob S. et al. The landscape of early infantile epileptic encephalopathy in a consanguineous population. Seizure 2019; 69: 154-172
• 15 Weeke LC, Brilstra E, Braun KP. et al. Punctate white matter lesions in full-term infants with neonatal seizures associated with SLC13A5 mutations. Eur J Paediatr Neurol 2017; 21 (02) 396-403
• 16 Whitney R, Choi E, Jones KC. The neuroimaging spectrum of SLC13A5 related developmental and epileptic encephalopathy. Seizure 2023; 106: 8-13
• 17 Mugisha N, Oliveira-Carneiro A, Behlim T, Oskoui M. Brain magnetic resonance imaging (mri) in spinal muscular atrophy: a scoping review. J Neuromuscul Dis 2023; 10 (04) 493-503
• 18 Scheffer H, Cobben JM, Matthijs G, Wirth B. Best practice guidelines for molecular analysis in spinal muscular atrophy. Eur J Hum Genet 2001; 9 (07) 484-491
• 19 Zhou J, Tawk M, Tiziano FD. et al. Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. Am J Hum Genet 2012; 91 (01) 5-14
• 20 Gan JJ, Garcia V, Tian J. et al. Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy. Neuromuscul Disord 2015; 25 (12) 959-963